Results 201 to 210 of about 45,933 (222)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Annals of Oncology, 2017
R Sabbatini, F Cheung, Vichien Srimuninnimit   +2 more
exaly  

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma

Annals of Oncology, 2013
Si-Hyung Lee, Sun Young Rha, H Y Lim
exaly  

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

Annals of Oncology, 2016
Hope Rugo, Marianne Pavel, G N Hortobagyi   +2 more
exaly  

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Annals of Oncology, 2017
Nicola Fazio, Jaume Capdevila, Eric Van Cutsem   +2 more
exaly  

A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes

Annals of Oncology, 2013
K U Park, S M Lim, H J Yun
exaly  

A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas

Annals of Oncology, 2016
D H Yoon, H J Kang, Y R Do
exaly  

Phase 3 trial of everolimus for metastatic renal cell carcinoma† ‡

Cancer, 2010
Robert Motzer, Alain Ravaud, Sergio Bracarda   +2 more
exaly  

Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)†

Annals of Oncology, 2016
Robert Motzer, Boris Y Alekseev, R J Motzer   +2 more
exaly